Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Biological+Products%22&type=Subject&filter%5B%5D=collection%3ACTG
/vufind/Search/Results?lookfor=%22Biological+Products%22&type=Subject&filter%5B%5D=collection%3ACTG
Search /vufind/Search2/Results?lookfor=%22Biological+Products%22&type=Subject&filter%5B%5D=collection%3ACTG
PubPharm (8)
1
The level of synovial biomarkers following platelet-rich plasma injection for knee osteoarthritis related to radiographic severity : The level of synovial biomarkers following platelet-rich plasma injection for knee osteoarthritis related to radiographic severity
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
The level of synovial biomarkers following platelet-rich plasma injection for knee osteoarthritis related to radiographic severity : The level of synovial biomarkers following platelet-rich plasma injection for knee osteoarthritis related to radiographic severity
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis : Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis - Orencia Atherosclerosis And Rheumatoid Arthritis Study(ORACLE Arthritis Study)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis : Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis - Orencia Atherosclerosis And Rheumatoid Arthritis Study(ORACLE Arthritis Study)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA : A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
6
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA : A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
7
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA : A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
8
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA : A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. - NA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
8
Aufsätze
8
E-Artikel
8
E-Ressourcen
Zeitschriftentitel
8
WHO International Clinical Trials Registry Plat...
Thema
8
610
6
Study Type: Interventional
4
Medical Condition: Asthma is a chronic inflamma...
4
Recruitment Status: Not yet recruiting
2
Medical Condition: Although most major guidelin...
2
Medical Condition: RA patients aged 20 years or...
2
Recruitment Status: Completed
2
Recruitment Status: Recruiting
2
Study Type: Observational
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2020-
4
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
8
Englisch
Haven't found what you're looking for?
Wird geladen...